NBI-1065890
NBI-1065890-TD2033
Phase 2 small_molecule active
Quick answer
NBI-1065890 for Tardive Dyskinesia is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Tardive Dyskinesia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active